Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: a retrospective study

Chen, Yonghua; Liu, Chunli; Lu, Wenju; Li, Mengxi; Hadadi, Cyrus A.; Wang, Elizabeth Wenqian; Yang, Kai; Lai, Ning; Huang, Junyi; Li, Shiyue; Zhong, Nanshan; Zhang, Nuofu; Wang, Jian

doi:10.21037/jtd.2016.02.58

Cited by 19 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The distribution of causes of death was similar to the most common symptoms that caused patient hospitalization in the Chen et al study. The majority of patients were hospitalized for dyspnea (93.5%), cough (89.8%), and sputum (79.7%) rather than symptoms caused by PH or HF, such as edema (8.2%) ( Chen et al, 2016 ).…”

Section: Discussionmentioning

confidence: 99%

Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease

Wang

Liao

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Patients with chronic obstructive pulmonary disease (COPD) are at risk for pulmonary hypertension (PH). The aim of our study was to investigate the benefit of statins for PH in patients with COPD.Methods: The study enrolled 23 million individuals from Taiwan’s population database from January 1, 2002, to December 31, 2017. COPD patients who met the inclusion criteria were enrolled, and patients with lung cancer, less than one year of observation, specific drug therapy for PH and lung transplantation were excluded.Results: A total of 643,131 COPD patients were included in the study, and only 12,308 patients developed PH during follow-up. Based on the inclusion and exclusion criteria, 8,577 PH patients were included in the cohort of patients with PH related to COPD for analysis. According to the definition of statin exposure, the final study population had 1,487 statin users and 7,090 statin non-users. The statin user group had a lower mortality related to PH than the non-user group (3.87 vs. 5.55 per 100 person-years, p < 0.001). The mortality rate for PH in the multivariate analysis (aHR = 0.78, 95% CI = 0.62–0.98, p = 0.046) was significantly lower for statin users than for non-users.Conclusion: Statins seem to benefit patients with PH and COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease

Wang

Liao

2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…This cross-sectional and observational study was conducted at a medical Center, Yixing People’s Hospital, affiliated with Jiangsu University, from January 1, 2019, to December 31, 2020. Subjects were invited to participate at the Respiratory and Critical Care Clinic, where their demographic information, pulmonary artery systolic pressure (PASP), 8 laboratory tests, Modified British Medical Research Council Questionnaire (mMRC), Chronic Obstructive Pulmonary Disease assessment test (CAT) scores, 9 Charlson’s Comorbidity Index Questionnaire (CCI), 10 Gastrointestinal Symptom Rating scale (GSRs), and lung function test was obtained. The study was approved by the Ethical Committee of the Affiliated Yixing Hospital of Jiangsu University (Batch No.2019-002).…”

Section: Methodsmentioning

confidence: 99%

“…This cross-sectional and observational study was conducted at a medical Center, Yixing People's Hospital, affiliated with Jiangsu University, from January 1, 2019, to December 31, 2020. Subjects were invited to participate at the Respiratory and Critical Care Clinic, where their demographic information, pulmonary artery systolic pressure (PASP), 8…”

Section: Methodsmentioning

confidence: 99%

Associations of Clinical Characteristics and Intestinal Flora Imbalance in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients and the Construction of an Early Warning Model

Zeng¹,

Yang²,

Yan³

et al. 2021

COPD

View full text Add to dashboard Cite

Objective Establish a simple predictive model and scoring rule that is suitable for clinical medical staff in respiratory departments to assess intestinal flora imbalance occurrence in stable chronic obstructive pulmonary disease (COPD) patients. Methods From January 1, 2019, to December 31, 2020, COPD patients (195 cases) – who attended the Outpatient Department, Respiratory and Critical Care, Yixing Hospital, Jiangsu University – were enrolled in a cross-sectional study. Based on stool examination results, patients were divided into experimental (41 cases) and control (154 cases) groups. Single-factor and logistic regression analyses were performed with the baseline data of the two groups to obtain a new predictive model, which was further simplified. Results Five predictive factors composed the model: body mass index (BMI), serum albumin (ALB), Charlson’s Comorbidity Index (CCI), gastrointestinal symptom score (GSRs), and Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. The model to predict intestinal flora imbalance in stable COPD patients had an area under the ROC curve (AUC) of 0.953 [95% CI (0.924, 0.982)]. After simplifying the scoring rules, the AUC was 0.767 [95% CI (0.676, 0.858)]. Conclusion In the current study, we obtained a model that could effectively predict intestinal flora imbalance risk in stable COPD patients, being suitable for implementation in early treatments to improve the prognosis. Moreover, all indicators can be easily and simply obtained.

show abstract

“…Firstly, given this is a local study conducted in Hong Kong, the PHTN results should be validated using the data from other databases in other countries. Secondly, medical history, such as smoking, asbestos, and family history, and clinical parameters such as partial pressure of oxygen (PaO2) and N-terminal pro-brain natriuretic peptide (NT-proBNP), which are associated with PHTN in other literature, were not included in this predictive model given the lack of the codes in CDARS (32). Thirdly, given the retrospective nature of this study, the results may be subjected to instabilities of the laboratory results, including the equipment modifications and blood samples artifacts, and changes in the clinical criteria for the diagnosis of the PHTN.…”

Section: Strength and Limitations Of The Studymentioning

confidence: 99%

Development of an Electronic Frailty Index for Predicting Mortality and Complications Analysis in Pulmonary Hypertension Using Random Survival Forest Model

Zhou

Chou

Wong³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundThe long-term prognosis of the cardio-metabolic and renal complications, in addition to mortality in patients with newly diagnosed pulmonary hypertension, are unclear. This study aims to develop a scalable predictive model in the form of an electronic frailty index (eFI) to predict different adverse outcomes.MethodsThis was a population-based cohort study of patients diagnosed with pulmonary hypertension between January 1st, 2000 and December 31st, 2017, in Hong Kong public hospitals. The primary outcomes were mortality, cardiovascular complications, renal diseases, and diabetes mellitus. The univariable and multivariable Cox regression analyses were applied to identify the significant risk factors, which were fed into the non-parametric random survival forest (RSF) model to develop an eFI.ResultsA total of 2,560 patients with a mean age of 63.4 years old (interquartile range: 38.0–79.0) were included. Over a follow-up, 1,347 died and 1,878, 437, and 684 patients developed cardiovascular complications, diabetes mellitus, and renal disease, respectively. The RSF-model-identified age, average readmission, anti-hypertensive drugs, cumulative length of stay, and total bilirubin were among the most important risk factors for predicting mortality. Pair-wise interactions of factors including diagnosis age, average readmission interval, and cumulative hospital stay were also crucial for the mortality prediction. Patients who developed all-cause mortality had higher values of the eFI compared to those who survived (P < 0.0001). An eFI ≥ 9.5 was associated with increased risks of mortality [hazard ratio (HR): 1.90; 95% confidence interval [CI]: 1.70–2.12; P < 0.0001]. The cumulative hazards were higher among patients who were 65 years old or above with eFI ≥ 9.5. Using the same cut-off point, the eFI predicted a long-term mortality over 10 years (HR: 1.71; 95% CI: 1.53–1.90; P < 0.0001). Compared to the multivariable Cox regression, the precision, recall, area under the curve (AUC), and C-index were significantly higher for RSF in the prediction of outcomes.ConclusionThe RSF models identified the novel risk factors and interactions for the development of complications and mortality. The eFI constructed by RSF accurately predicts the complications and mortality of patients with pulmonary hypertension, especially among the elderly.

show abstract

Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: a retrospective study

Cited by 19 publications

References 25 publications

Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease

Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease

Associations of Clinical Characteristics and Intestinal Flora Imbalance in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients and the Construction of an Early Warning Model

Development of an Electronic Frailty Index for Predicting Mortality and Complications Analysis in Pulmonary Hypertension Using Random Survival Forest Model

Contact Info

Product

Resources

About